Moreover, a prognostic model was established based on the ceRNA network, and the AC005154.6/hsa-miR-29c-3p/CCNL2 axis provided guidance for the diagnosis, targeted therapy, and immunotherapy of prostate cancer. This evidence concerns the gene CCNL2 and prostate cancer.